“…NB NOS samples have also been quantified (n=41, 9%). Various techniques were performed to assess the status of the MYCN oncogene: MNNA (n=379, 82.8%) vs. MNA (n=77, 16.8%), the integrity of the 11q23 region: non-deleted (n=321, 70.1%) vs. 11qD (n=77, 16.8%) and the overall genomic profile: numerical chromosomal aberrations (n=95, 20.7%) vs. SCA (n=223, 48.7%), following previously published European guidelines [ 35 - 39 ]. The combination of all the above histopathological and genetic variables with age: <18 months (n=266, 58.1%) vs. >18 months (n=172, 37.6%); and stage: localized 1 (n=145, 31.6%), localized 2 (n=143, 31.4%), metastatic (n=112, 24.4%) and metastatic special (n=32, 6.9%); according to the INRG classification, defined a risk group: very low (n=184, 37.6%), low (n=77, 37.6%), intermediate (n=34, 37.6%), unspecified low or intermediate (some data missing) (n=24, 5.3%) and high (n=110, 37.6%) (Figure 4 ) [ 2 ].…”